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Abstract 
Background: The HIV‑1 infection is characterized by profound CD4+ T cell destruction and a marked Th17 dysfunc‑
tion at the mucosal level. Viral suppressive antiretroviral therapy restores Th1 but not Th17 cells. Although several key 
HIV dependency factors (HDF) were identified in the past years via genome‑wide siRNA screens in cell lines, molecular 
determinants of HIV permissiveness in primary Th17 cells remain to be elucidated.
Results: In an effort to orient Th17‑targeted reconstitution strategies, we investigated molecular mechanisms of 
HIV permissiveness in Th17 cells. Genome‑wide transcriptional profiling in memory CD4+ T‑cell subsets enriched in 
cells exhibiting Th17 (CCR4+CCR6+), Th1 (CXCR3+CCR6−), Th2 (CCR4+CCR6−), and Th1Th17 (CXCR3+CCR6+) features 
revealed remarkable transcriptional differences between Th17 and Th1 subsets. The HIV‑DNA integration was supe‑
rior in Th17 versus Th1 upon exposure to both wild‑type and VSV‑G‑pseudotyped HIV; this indicates that post‑entry 
mechanisms contribute to viral replication in Th17. Transcripts significantly enriched in Th17 versus Th1 were previ‑
ously associated with the regulation of TCR signaling (ZAP‑70, Lck, and CD96) and Th17 polarization (RORγt, ARNTL, 
PTPN13, and RUNX1). A meta‑analysis using the NCBI HIV Interaction Database revealed a set of Th17‑specific HIV 
dependency factors (HDFs): PARG, PAK2, KLF2, ITGB7, PTEN, ATG16L1, Alix/AIP1/PDCD6IP, LGALS3, JAK1, TRIM8, MALT1, 
FOXO3, ARNTL/BMAL1, ABCB1/MDR1, TNFSF13B/BAFF, and CDKN1B. Functional studies demonstrated an increased 
ability of Th17 versus Th1 cells to respond to TCR triggering in terms of NF‑κB nuclear translocation/DNA‑binding 
activity and proliferation. Finally, RNA interference studies identified MAP3K4 and PTPN13 as two novel Th17‑specific 
HDFs.
Conclusions: The transcriptional program of Th17 cells includes molecules regulating HIV replication at multiple 
post‑entry steps that may represent potential targets for novel therapies aimed at protecting Th17 cells from infection 
and subsequent depletion in HIV‑infected subjects.
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Background
The Th17 cells represent a distinct lineage of CD4+ 
T-cells characterized by the expression of specific 
transcription factors (e.g., RORγt, RORA, and STAT3) 
and cytokines (e.g., IL-17A, IL-17F, IL-21, IL-22, IL-26, 
IL-8, and CCL20) [1–5]. Th17 cells represent unique 
players in immunity against pathogens at mucosal bar-
rier surfaces where they orchestrate the functionality of 
epithelial cells, neutrophils, and B cells [3, 6, 7, 8, 9, 10]. 
Recruitment of Th17 cells into mucosal sites is medi-
ated in part by the homing receptor CCR6/CCL20, with 
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CCR6 being a well-established Th17 surface marker 
[11, 12]. Other homing receptors, such as CCR4 and 
CXCR3, distinguish between Th17 subsets with dis-
tinct antigenic specificity and effector cytokine expres-
sion: CCR4+CCR6+Th17 and CXCR3+CCR6+Th1Th17 
[13–15]. During chronic HIV/SIV infections, the deple-
tion of Th17 cells from gut-associated lymphoid tissues 
(GALT) leads to dramatic alterations of the mucosal bar-
rier integrity, alterations that cause microbial transloca-
tion, chronic immune activation, and disease progression 
[16–28]. Studies in SIV models demonstrated an inverse 
correlation between peak and set point viral loads as well 
as the preexisting mucosal Th17 pool [29]; this strength-
ens the concept that Th17 cells significantly contribute to 
anti-viral immunity at mucosal sites [30]. Studies in HIV-
infected subjects demonstrated that the preservation of 
mucosal Th17 cells is associated with slow disease pro-
gression [31–36]. Despite the success of current antiret-
roviral therapies (ART) in reducing viral replication to 
undetectable plasma levels, the pool of Th17 cells is not 
fully restored at mucosal sites or in the peripheral blood 
of infected subjects [22, 31, 37, 38, 39]. Recent studies 
demonstrated that ART initiation during early but not 
late acute HIV infection preserves Th17 counts and their 
effector functions [40, 41]. However, early HIV diagnosis 
remains, however a challenge even in high income coun-
tries; this emphasizes the need for alternative strategies 
with the goal of Th17 preservation and/or restoration 
during chronic HIV infection.
The mechanisms underlying Th17 depletion dur-
ing HIV/SIV infections include altered trafficking into 
mucosal sites [42, 43]; altered ratios between regula-
tory T-cells (Tregs) and Th17 cells [44, 45]; depletion 
of mucosal CD103+ dendritic cells (DC) [46], a subset 
involved in Th17 differentiation [47, 48]; limited IL-21 
availability, a cytokine critical for Th17 survival [27]; and/
or over expression of negative regulators of Th17 differ-
entiation [49]. In addition, studies by our group and oth-
ers provided evidence that infection per se contributes to 
the depletion of memory Th17 cells [37, 38, 50] and the 
paucity of naive-like Th17 precursors [39, 51]. Despite 
their massive depletion, fractions of Th17 cells are long 
lived [52–54] and likely contribute to HIV persistence 
under ART [55] (Wacleche, Ancuta et  al, unpublished 
observations). Genome-wide RNA interference stud-
ies performed in distinct cell lines identified large sets of 
HIV dependency factors (HDFs) and revealed the molec-
ular complexity of virus-host cell interactions [56–60]. 
Nevertheless, the molecular determinants of HIV per-
missiveness in primary Th17 cells are not fully under-
stood. This knowledge is essential for designing novel 
targeted therapies aiming at limiting HIV replication and 
persistence specifically in Th17 cells.
In this study, we investigated transcriptional and func-
tional differences between primary memory CD4+ T-cell 
subsets enriched in Th17 (CCR4+CCR6+) and Th1 
(CXCR3+CCR6−) polarized cells, subsets that we previ-
ously reported to be permissive and resistant to infection 
with R5 or X4 HIV strains, respectively [37]. Our study 
revealed the existence of HDFs specifically expressed by 
Th17 cells that may be used as targets for novel therapeu-
tic strategies aiming at limiting HIV replication and pre-
serving the quality of Th17-mediated mucosal immunity 
in HIV-infected subjects.
Results
Identification of a molecular signature associated with HIV 
permissiveness in Th17 cells at entry and post‑entry levels
We previously demonstrated that subsets of mem-
ory CD4+ T-cells enriched in Th17 and Th1Th17 
cells are highly permissive to R5 and X4 HIV infec-
tion; Th2-enriched fractions replicate X4 HIV only; 
while Th1-enriched fractions replicated R5 and X4 
HIV at relatively low levels [37]. Except for Th2 cells 
that lack CCR5 expression, differences in HIV rep-
lication between Th17 and Th1 are not explained by 
differential expression of CCR5 or CXCR4 [37, 38]. 
To identify HIV-dependency factors (HDFs) in pri-
mary Th17 cells, we performed a genome-wide analy-
sis of gene expression in memory CD4+ T-cell subsets 
enriched in Th1, Th2, Th17, and Th1Th17 cells sorted by 
FACS and stimulated by CD3/CD28 Abs, as previously 
described [37]. These subsets were identified based on 
the differential expression of the well-established sur-
face markers CCR4, CCR6, and CXCR3, as previously 
described [13, 15, 37] and illustrated in Fig.  1a: Th1 
(CXCR3+CCR4−CCR6−), Th2 (CXCR3−CCR4+CCR6−), 
Th17 (CXCR3−CCR4+CCR6+), and Th1Th17 
(CXCR3+CCR4−CCR6+). Total mRNA extracted 
from each subset was hybridized onto the Illumina 
HumanHT-12 v4 Expression BeadChip (GEO access 
number GSE70396) and transcripts up- and down regu-
lated in Th17 compared to Th1, Th2, or Th1Th17 were 
identified based on p values (p < 0.05) or adjusted p val-
ues (adj. p < 0.05) and fold change (FC) expression ratios 
(cut-off 1.3-fold) (Additional file  1: Table S1; Additional 
file  2: Table S2). The most robust differences in gene 
expression were observed between Th17 versus Th1 
(Fig. 1b) with 1630 (p < 0.05) and 1,081 (adj. p < 0.05) up 
regulated and 1409 (p < 0.05) and 772 (adj. p < 0.05) down 
regulated probe sets (FC cut-off 1.3) (Additional file  1: 
Table S1; Additional file 2: Table S2; Additional file 3: Fig-
ure S1a). To orient our genome-wide search for HDFs, we 
investigated whether HIV permissiveness in Th17 versus 
Th1 was modulated at entry as opposed to post-entry 
levels. With this in mind, HIV-DNA integration was 
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quantified in cells exposed to replication-competent R5 
HIV (NL4.3BaL-GFP) or single-round VSV-G-pseudo-
typed HIV (VSVG-HIV-GFP) entering cells by endocyto-
sis independently of CD4 and co-receptors [61]. Results 
in Fig.  1c, d reveal superior HIV-DNA integration in 
Th17 versus Th1 upon exposure to both NL4.3BAL-GFP 
and VSVG-HIV-GFP strains; this indicates that post-
entry mechanisms contribute to HIV permissiveness in 
Th17 cells. This evidence led to the prediction that tran-
scripts enriched in Th17 as compared to Th1 include 
HDFs acting at the post-entry level.
Top differentially expressed transcripts (adj. p  <  0.05, 
FC  >  2.5) in Th17 versus Th1 included well-established 
markers for Th17 (i.e., IL-22, CCR6, KLRB1, IL-17F, 
CCL20, RORC, IL-26, and PPARG) and Th1 (i.e., IFN-
γ, CCL5, CCL4L2, CCL3, CCL3L3, and CXCR3); this 
provides a first validation for our transcriptional stud-
ies (Tables  1, 2). The list of top up regulated genes also 
included transcripts that likely represent new functional 
markers for Th17 cells: PTPN13 (APO-1/CD95 (Fas)-
Associated Phosphatase) [62], CHN1, GPR56, LGMN, 
CTSH, KLF2, CACNA1l, RARRES3, Ly9, TNFSF13B, 
NFL2, PI16, MXD4, HPGD, SNX29, P2RY5, ZNF381, 
LIME1, MAP3K4, CD96, GPR15, and GLIPR1 (Table 1). 
Importantly, NFIL3, a documented inhibitor of Th17 
polarization in mice [63], was found down regulated in 
human Th17 versus Th1 (Table  2); this suggests a con-
served mechanism involved in the regulation of Th17 
polarization in humans and mice.
Gene Set Variation Analysis (GSVA) of differentially 
expressed genes (p  <  0.05; FC cut-off 1.3) identified 
canonical pathways (C2) enriched in Th17 versus Th1, 
including those linked to circadian repression of expres-
sion by REV-ERBα, nuclear receptor transcription, T 
helper differentiation, CSK signaling, TCR signaling, 
Ras, anthrax, IL-7 signaling, phosphorylation of CD3 and 
TCR zeta, PTEN, ABCA transporters in lipid homeosta-
sis, RhoA, longevity pathway, MEF2D signaling, the role 
of Nef in HIV replication, and TNF signaling (Fig.  1e). 
The GSVA also identified pathways down regulated in 
Th17 versus Th1, including pathways linked to metal 
ion SLC transporters, zinc transporters, STEM, glucose 
transport, extension of telomeres, protein synthesis as 
well as transcription initiation and termination (Addi-
tional file 3: Figure S1b; Additional file 4: Table S3). These 
results reveal overrepresentation of specific transcripts 
and cellular functions in Th17 versus Th1, with pathways 
enriched in Th17 cells likely being essential for both Th17 
polarization and HIV permissiveness.
Consistent with the GSVA results (Fig.  1e), Gene 
Ontology classification of differentially expressed genes 
(p  <  0.05; FC cut-off 1.3) revealed transcripts related 
to different biological functions including: cytokines/
chemokines, TCR, and transcription regulators (Fig. 2a–
c). In the cytokines/chemokines category, genes up regu-
lated in Th17 versus Th1 included known Th17-specific 
cytokines (IL-22, CCL20, IL-26) and chemokine recep-
tors (CCR6), as well as TNFSF15 (TNF superfamily), 
TNFRSF25 (TNF receptor superfamily), TNFSF13B, 
IL-10RB, IL-11RA, CLCF1 (cardiotrophin-like cytokine 
factor), IL-15, IL-17RA, IL-7R, and TGFBR2 (TGF-β 
receptor) transcripts (Fig. 2a). Genes up regulated in Th1 
versus Th17 included the Th1 marker CXCR3, IFNG, 
several CCR5 binding ckemokines (CCL5, CCL4L2, 
CCL3L1, CCL3L3, CCL3), and also transcripts for LTA 
(lymphotoxin α), IL-9, IL-3, CCL17, IL-5, IL-4, XCL1, 
TNFSF9, TNFSF14, CXCR5, TNFRSF8, IL-6, CSF1R, 
LIF, IL-2RA, IL3RA, and IL15RA (Fig.  2a). Despite the 
fact that IL-4 and IL-5 transcripts were found up regu-
lated in Th1 versus Th17 cells, levels of their expression 
in Th1 compared to Th2 cells were significantly lower 
(data not shown). Such false positive signals are expected 
in high throughput screenings and therefore the require-
ment for subsequent validations for any important hit 
is mandatory. Transcripts related to the TCR signaling 
cascade such as IKBKB (inhibitor of NF-κB kinase beta) 
(See figure on previous page.) 
Fig. 1 Identification of a molecular signature associated with HIV permissiveness in CCR4+CCR6+ Th17 cells. Total CD4+ T‑cells were isolated from 
PBMCs of HIV‑uninfected subjects by negative selection using magnetic beads. Cells were labeled with a cocktail of CD45RA, CD8, CD19, CD56, CCR4, 
CCR6, and CXCR3 Abs. a Shown is the gating strategy used for the FACS sorting of the following four memory (CD45RA−) CD4+ subsets lacking 
CD8, CD19, and CD56 expression: CXCR3+CCR4−CCR6− (Th1), CXCR3−CCR4+CCR6− (Th2), CXCR3−CCR4+CCR6+ (Th17), and CXCR3+CCR4−CCR6+ 
(Th1Th17). Shown are results from one donor representative of results generated with cells from >10 HIV‑uninfected donors. b Highly pure matched 
Th1, Th2, Th17, and Th1Th17 subsets were sorted by FACS (n = 5) and stimulated via CD3/CD28 for 3 days. Total RNA was reverse transcribed into 
cDNA and hybridized onto the Human HT‑12 v4 Expression BeadChip (Illumina) for genome‑wide transcriptional profiling. One‑way ANOVA analysis 
was performed to identify differentially expressed genes based on p value < 0.05 and fold change (FC, cut‑off 1.3). Shown are volcano plots for all 
probes in each linear model with the FC on the x axis and the negative logarithm of the adjusted p values adjusted for false discovery rate (FDR) 
on the y axis. Red/green color code is based on the 5 % FDR threshold. c, d Cell subsets were stimulated via CD3/CD28 for 3 days and exposed to 
replication competent NL4.3BAL‑GFP (c) and single round VSVG‑HIV‑GFP strains (d). Shown is real‑time quantification of HIV‑DNA integration at day 
three post‑infection (mean ± SD of triplicate wells) in matched subsets isolated from n = 3 different donors. e Shown are the top 50 pathways up 
regulated in Th17 versus Th1 cells; heat map of the individual enrichment statistics (ES) from a gene set variation analysis (GSVA) for pathways differ‑
entially expressed between Th1 and Th17 cells with a FDR inferior to 1 %. Transcriptional profiles in a, b, and e were generated with cells stimulated 
via CD3/CD28 but unexposed to HIV
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[64], PAK2 (p21-activated kinase 2) [65], CD3G, TRAT1 
(T-cell receptor associated transmembrane adaptor 1), 
PTEN (phosphatase and tensin homolog) [66], Lck [67], 
FYB, PAG1, MALT1 [68, 69], PIK3CA, PRKCQ, CD247/
CD3ε, ZAP70 [70], EVL, INPP5D, PIK3R1, WAS, RIPK2, 
PTPRC, PLCG1, ITK, CARD11, CD3D, and NCK1, were 
selectively enriched in Th17 versus Th1 (Fig. 2b). Of note, 
PAK2 [65] and ZAP70 [71] were previously linked to effi-
cient HIV replication in T cells. Finally, major differences 
between Th17 and Th1 were observed for the expression 
of Transcription regulators. In addition to known tran-
scription factors involved in the regulation of Th17 polar-
ization (RORA, RORC, RUNX1) [72] and Th1 (Eomes) 
[73], other transcripts such as IRF1, STAT1, IRF3, KLF2, 
E2F2, IRF9, SMAD3, ARNTL, PPARG, and FOXO3 were 
found up regulated, while IRF4, IRF8, MYC, and Notch1 
were down regulated in Th17 versus Th1 (Fig. 2c).
Similar to GSVA and GO, Gene Set Enrichment Analy-
sis (GSEA) [74] identified top genes linked to canonical 
pathways (TCR signaling: PAK2, Lck, ZAP-70, CD96), 
transcription factors (RORC, RUNX1), and biologi-
cal processes (stress activated protein kinase signal-
ing: MAP4K1, MAP3K4, MAP3K5; protein amino acid 
dephosphorylation: PTPN12, PTPN13, PTPN22) as 
being up regulated in Th17 versus Th1 cells (Additional 
file 5: Figure S2).
We also performed a meta-analysis to identify tran-
scripts enriched in Th17 versus Th1 that overlapped 
with those listed on the National Center for Biotech-
nology Information (NCBI) interaction database in the 
Table 1 Top up regulated transcripts in CCR4+CCR6+ Th17 versus CXCR3+CCR6− Th1
p p value; adj. p adjusted p value, FC fold change
Symbol p adj. p FC Gene definition
IL‑22 1.0E−04 4.0E−03 11.9 Interleukin 22
CCR6 1.7E−06 3.7E−04 9.7 Chemokine (C–C motif ) receptor 6
PTPN13 1.5E−09 8.9E−06 9.6 Protein tyrosine phosphatase, non‑receptor type 13 (APO‑1/CD95 
(Fas)‑associated phosphatase)
KLRB1 1.5E−05 1.2E−03 7.0 Killer cell lectin‑like receptor subfamily B, member 1
IL‑17F 5.9E−05 2.9E−03 6.6 Interleukin 17F
CCL20 3.2E−04 8.2E−03 6.6 Chemokine (C–C motif ) ligand 20
RORC 2.1E−05 1.5E−03 6.6 RAR‑related orphan receptor C, transcript variant
IL‑26 9.3E−06 9.3E−04 5.1 Interleukin 26
GPR56 1.4E−03 2.0E−02 4.9 G protein‑coupled receptor 56, transcript variant 2
LGMN 1.6E−05 1.3E−03 4.5 Legumain, transcript variant 2
CTSH 1.5E−03 2.1E−02 4.4 Cathepsin H, transcript variant 1
KLF2 1.7E−03 2.2E−02 3.8 Kruppel‑like factor 2 (lung)
RARRES3 4.9E−03 4.3E−02 3.5 Retinoic acid receptor responder 3
Ly9 8.6E−06 8.8E−04 3.5 Lymphocyte antigen 9, transcript variant 2
TNFSF13B 2.1E−05 1.5E−03 3.5 Tumor necrosis factor superfamily, member 13b
NLF2 2.8E−03 3.1E−02 3.4 Nuclear localized factor 2
PI16 6.1E−09 1.7E−05 3.3 Peptidase inhibitor 16
MXD4 1.1E−07 9.8E−05 3.3 MAX dimerization protein 4
HPGD 4.1E−06 5.9E−04 3.3 Hydroxyprostaglandin dehydrogenase 15‑(NAD)
SNX29 1.9E−05 1.4E−03 3.2 Sorting nexin 29
TRIB2 2.5E−07 1.4E−04 3.2 Tribbles homolog 2
P2RY5 2.3E−07 1.3E−04 3.1 Purinergic receptor P2Y, G‑protein coupled, 5
ZNF381 6.4E−06 7.3E−04 3.0 Zinc finger protein 831
LIME1 1.1E−03 1.8E−02 2.9 Lck interacting transmembrane adaptor 1
MAP3K4 4.3E−07 1.7E−04 2.9 Mitogen‑activated protein kinase kinase kinase 4
CD96 1.0E−05 9.8E−04 2.8 CD96 molecule, transcript variant 1
GPR15 1.7E−06 3.7E−04 2.8 G protein‑coupled receptor 15
PPARG 3.2E−06 5.1E−04 2.7 Peroxisome proliferator‑activated receptor gamma
GLIPR1 6.4E−06 7.3E−04 2.6 GLI pathogenesis‑related 1
CD52 3.1E−04 3.2E−03 2.3 CD52 molecule
ARNTL 3.4E−04 8.4E−03 2.2 Aryl hydrocarbon receptor nuclear translocator‑like
FOXO3 5.0E−03 4.3E−02 1.7 Forkhead box O3 (FOXO3), transcript variant 2, mRNA
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categories “HIV-1 proteins enhanced by expression of 
human genes” (Fig. 3) and “HIV-1 proteins interact with” 
(Additional file  6: Figure  S3). Such transcripts included 
PTEN (a negative regulator of the mTOR pathway [75]), 
KLF2 [76], ITGB7 (a gut-homing molecule and an alter-
native HIV-binding receptor [77]), ATG16L1 (a regulator 
of autophagy, a pathway associated with HIV intracellu-
lar degradation [78, 79]), PDCD6IP (AIP1/Alix, a com-
ponent of the HIV budding machinery [80]), JAK1 (a 
tyrosine kinase that phosphorylates STAT3 [60]), TRIM8 
(a regulator of NF-κB and STAT3-dependent signaling 
cascades [81, 82] and a documented HDF [57]), LGALS3 
(an HIV Tat-induced glycoprotein recently reported to 
promote HIV budding by association with Alix [79, 83]), 
FOXO3 [84], ARNTL [84] (Fig. 3), ABCB1 (a drug efflux 
pump associated with resistance to antiretroviral and 
anti-cancer drugs [85]), TNFSF13B/BAFF (a gene tar-
geted by HIV for integration [86]), RUNX1 (a transcrip-
tion factors involved in HIV latency [87]), PAK2 [65], and 
CDKN1B/p27kip1 (Additional file 6: Figure S3).
Real-time RT-PCR quantifications were performed for 
transcripts previously reported to be involved in the regu-
lation of HIV replication (KLF2, PPARG), Th17 polariza-
tion (ARNTL/BMAL1), and TCR signaling (Lck, ZAP-70) 
as well as PTPN13, which may represent a new Th17 func-
tional marker. Consistent with the microarrays, results in 
Fig. 4 demonstrate preferential expression of KLF2, PPARG, 
ARNTL, Lck, ZAP-70, and PTPN13 in Th17 versus Th1.
In conclusion, genome-wide transcriptional profiling 
revealed differences in gene expression between human 
Th17 and Th1 subsets, validated previously described 
cell-specific transcripts, and identified a large panel of 
Table 2 Top down regulated transcripts in CCR4+CCR6+ Th17 vs. CXCR3+CCR6− Th1
p p value, adj. p adjusted p value; FC, fold change
Symbol p adj. p FC Definition
IL‑9 2.7E−07 1.4E−04 −46.7 Interleukin 9
GZMK 9.7E−05 3.9E−03 −17.1 Granzyme K (granzyme 3; tryptase II)
IFN‑γ 8.5E−04 1.5E−02 −16.7 Interferon gamma
CCL5 3.8E−05 2.2E−03 −11.9 Chemokine (C–C motif ) ligand 5
GZMH 1.4E−04 4.8E−03 −11.7 Granzyme H (cathepsin G‑like 2, protein h‑CCPX)
IL‑3 2.2E−08 2.7E−05 −11.2 Interleukin 3 (colony‑stimulating factor, multiple)
NKG7 8.4E−05 3.6E−03 −9.1 Natural killer cell group 7 sequence
CCL4L2 5.1E−03 4.4E−02 −7.0 Chemokine (C–C motif ) ligand 4‑like 2
CCL3 5.3E−03 4.5E−02 −6.8 Chemokine (C–C motif ) ligand 3
EOMES 2.3E−07 1.3E−04 −6.6 Eomesodermin homolog (Xenopus laevis)
CCL3L1 3.9E−03 3.8E−02 −6.5 Chemokine (C–C motif ) ligand 3‑like 1
CCL3L3 5.2E−03 4.5E−02 −6.3 Chemokine (C–C motif ) ligand 3‑like 3
NAPSB 2.7E−03 3.0E−02 −6.1 Homo sapiens napsin B aspartic peptidase pseudogene (NAPSB)
BATF3 2.5E−08 2.8E−05 −5.9 Basic leucine zipper transcription factor, ATF‑like 3
NAPSA 3.1E−04 7.9E−03 −5.6 Napsin A aspartic peptidase
CXCR3 4.2E−04 9.7E−03 −5.2 Chemokine (C–X–C motif ) receptor 3
MATK 1.9E−07 1.2E−04 −4.9 Megakaryocyte‑associated tyrosine kinase, transcript variant 3
OSM 2.5E−06 4.7E−04 −4.3 Oncostatin M
IRF8 2.5E−05 1.7E−03 −4.2 Interferon regulatory factor 8
MAOA 3.0E−04 7.8E−03 −4.0 Monoamine oxidase A, nuclear gene encoding mitochondrial protein
DNAJC12 5.1E−04 1.1E−02 −3.9 DnaJ (Hsp40) homolog. subfamily C, member 12
MT1 J 6.1E−06 7.1E−04 −3.9 Metallothionein 1G
NPSR1 1.5E−05 1.2E−03 −3.9 Neuropeptide S receptor 1, transcript variant 1
ATP8B4 4.0E−05 2.2E−03 −3.8 ATPase. class I, type 8B. member 4
TIMD4 1.8E−05 1.4E−03 −3.8 T‑cell immunoglobulin and mucin domain containing 4
LTA 3.8E−05 2.2E−3 −3.7 Lymphotoxin alpha (TNF superfamily. member 1)
SERPINB6 2.1E−07 1.3E−04 −3.2 Serpin peptidase inhibitor, clade B (ovalbumin). member 6
PTK2 5.1E−03 4.4E−02 −2.7 PTK2 protein tyrosine kinase 2, transcript variant 2
CCL17 2.3E−05 1.6E−03 −2.6 Chemokine (C–C motif ) ligand 17
NFIL3 3.4E−03 3.5E−02 −2.5 Nuclear factor interleukin 3 regulated
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Fig. 2 Gene Ontology classification of differentially expressed genes in CCR4+CCR6+ Th17 versus CXCR3+CCR6− Th1 cells. Shown are heatmaps 
of differentially expressed genes (p < 0.05, FC cut‑off 1.3) selected for their biological functions as follows: a Cytokines (KEGG), b TCR signalling 
(reactome), and c transcription regulators (ingenuity). Coloring of the cells is scaled by the z score of each microarray probe individually. Results 
correspond to matched Th17 and Th1 subsets from n = 5 different HIV‑uninfected donors isolated and stimulated by CD3/CD28 Abs for 3 days as 
described in Fig. 1
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Fig. 3 Meta‑analysis using the NCBI HIV interaction database for the identification of HIV‑1 proteins enhanced by expression of human genes 
enriched in Th17 cells. Differentially expressed genes between Th17 and Th1 subsets (p < 0.05, FC cut‑off 1.3) were matched to the lists of human 
genes known to interact with HIV‑1 proteins. Shown are significant probes with the smallest p value for each overlapping gene. Heatmap cells are 
scaled by the expression level z scores for each probe individually
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new transcripts that may contribute to Th17 when com-
pared to Th1 lineage differentiation fate and/or HIV per-
missiveness at post-entry levels.
Th17 versus Th1 express higher Lck and ZAP‑70 levels
HIV replication is restricted in resting CD4+ T-cells 
[88–90] through mechanisms that are counteracted upon 
activation by the TCR and/or cytokines [60, 91, 92, 93, 94, 
95]. Ingenuity Pathway Analysis (IPA) performed on dif-
ferentially expressed genes (p < 0.05; FC cut-off 1.3) was 
used to illustrate transcripts enriched in Th17 versus Th1 
that are linked to TCR signaling (Additional file 7: Figure 
S4). The later transcripts included Lck and ZAP-70, two 
kinases associated with CD4 and CD3zeta, respectively, 
that play critical roles in the TCR downstream signaling 
cascade [67, 70]. ZAP-70 was reported to be essential 
for HIV-1 cell-to-cell transmission [71] and HIV-Nef-
mediated effects [96]. The Lck and ZAP-70 mRNA lev-
els were confirmed by RT-PCR as being significantly 
higher in Th17 versus Th1 (Fig. 4). Confocal fluorescence 
microscopy was used to visualize and quantify expres-
sion of total and phosphorylated Lck and ZAP-70 pro-
teins in cells upon 3 days of TCR triggering. The Z-stack 
reconstruction of 100× images visualized the localization 
of Lck both extra and intra-nuclear (Fig. 5a). The expres-
sion of total Lck, together with Lck phosphorylated on 
Tyr394 (a positive regulatory site [97]), was significantly 
higher in Th17 versus Th1 from 2/2 donors (Fig. 5b, upper 
and middle panels). In contrast, levels of the Lck phos-
phorylated on Tyr505 (a negative regulatory site [97]), 
were significantly lower in Th17 versus Th1 from 1/2 
donors (Fig. 5b, lower panel). In contrast, the localization 
of ZAP-70 was, as expected, mainly cytoplasmic (Fig. 5c). 
Although the expression of total ZAP-70 was signifi-
cantly higher in Th17 versus Th1 from 1/2 donors, levels 
of phosphorylated ZAP-70 were significantly higher in 
Th17 versus Th1 from both donors (Fig. 5d). These results 
suggest a potential superior expression and activation sta-
tus of Lck and ZAP-70 in response to TCR triggering in 
Th17 compared to Th1 cells. These differences are, how-
ever, minor, and this is consistent with minor differences 
observed in terms of Lck and ZAP-70 mRNA expression 
(Fig. 4).
Other downstream TCR signaling molecules overex-
pressed in Th17 versus Th1 include PAK2, PI3 K, and Fyn 
(Additional file 7: Figure S4). PAK2 is a well-established 
Fig. 4 Validation by RT‑PCR of superior KLF2, PPARγ, ARNTL, Lck, ZAP‑70, and PTPN13 mRNA expression in CCR4+CCR6+ Th17 versus CXCR3+CCR6− 
Th1 cells. Total RNA was extracted from Th17 and Th1 subsets isolated and stimulated via CD3/CD28 for 3 days as described in Fig. 1. Expression 
of KLF2, PPARγ, ARNTL, PTPN13, Lck, and ZAP‑70 mRNA was quantified by SYBR green real time RT‑PCR. Quantification was performed relative to a 
standard curve generated based on cDNA specific for each transcript. The expression of each gene was normalized to the 28S rRNA internal control 
(28S rRNA) and expressed as fgs RNA of a target gene per 1 ng rRNA28S. Depicted are results obtained with matched Th17 versus Th1 subsets 
isolated from n = 4 different HIV‑uninfected individuals. Paired t test values are indicated on the graphs. Fold change (FC) expression values in Th17 
versus Th1 are included in the graphs
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Fig. 5 Expression of total and phosphorylated Lck and ZAP70 proteins in CCR4+CCR6+ Th17 versus CXCR3+CCR6− Th1 cells. Matched Th17 and Th1 
subsets were isolated and stimulated by CD3/CD28 Abs for 3 days as described in Fig. 1. Cells were fixed on poly‑l‑lysine coated slides. Intracellular 
staining was performed with rabbit anti‑human Abs against total or phosphorylated Lck (a, b) and ZAP70 (c, d). DAPI was used to stain cell nuclei. 
Slides were observed by fluorescence microscopy using a spinning‑disc zeiss cell observer microscope. The visualization of total Lck (a) and ZAP70 
(c) expression was performed using a 100× oil objective (NA = 1.46) in a spinning‑disc confocal mode. Shown are maximum intensity z projection 
of z stack of matched Th17 and Th1 cells from one donor representative of observations made with cells from two different donors. The relative 
expression of total and phosphorylated Lck (b) and ZAP70 (d) was further quantified using the Image J software after observations made by epif‑
luorescence with a 40× oil objective (NA = 1.40). b, d Shown are expression of total‑Lck and total‑ZAP70 (upper panels) together with phosphos‑
phorylated Lck (Tyr 394, Tyr 505) and ZAP70 (middle and lower panels) in matched Th17 versus Th1 cells from two different donors (n = 50–100 cells 
per subsets). Horizontal red lines indicate median values. Unpaired t test p values are indicated on the figures
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target of HIV-Nef that contributes to viral replication 
[65]. PI3  K is required for HIV-1 Nef-mediated down-
regulation of cell surface MHC-I molecules [98]. Fyn has 
been demonstrated to be involved in NF-κB mediated 
HIV transcription [99]. In contrast, Grb2 (growth fac-
tor receptor-bound protein 2) was found down regulated 
in Th17 versus Th1 (Additional file 7: Figure S4). This is 
consistent with the fact that Grb2 inhibits the Tat-medi-
ated transactivation of HIV-1 LTR and subsequent viral 
replication [100] (Additional file 4: Table S3).
Altogether, these results demonstrate superior expres-
sion of signaling molecules associated with TCR signaling 
in Th17 versus Th1, including the active phosphorylated 
forms of Lck and ZAP-70. These differences very likely 
contribute to the superior ability of Th17 when compared 
to Th1 to respond to weak TCR signals, thus creating a 
cellular environment favorable to HIV replication.
Th17 versus Th1 exhibit superior NF‑κB nuclear 
translocation and DNA‑binding activity
The nuclear translocation of the transcription factor 
NF-κB is a key event in the signaling cascade of down-
stream TCR. NF-κB regulates transcription of numerous 
genes involved in T-cell activation and survival [101], and 
also binds to the HIV promoter to initiate viral genome 
transcription [102, 103]. Of note, transcripts for mucosa 
associated lymphoid tissue lymphoma translocation gene 
1 (MALT1), a paracaspase critical for NF-κB activation 
[68, 69], were enriched in Th17 versus Th1 (Additional 
file 1: Table S1). This evidence, together with the up-regu-
lation of TRIM8 [82] transcripts in Th17 versus Th1, sug-
gests superior NF-κB activity in Th17 cells. To investigate 
this possibility, we first used confocal fluorescence micros-
copy to visualize and quantify expression of NF-κB in the 
nuclei of Th17 versus Th1 upon TCR triggering. In both 
Th17 and Th1, NF-κB was mainly localized in the nucleus; 
however, the intensity of intra-nuclear staining was signif-
icantly higher in Th17 than Th1 in 2/2 donors (Fig. 6a, b). 
In parallel, an ELISA-based assay was used to quantify the 
NF-κB DNA-binding activity in the nuclear fractions iso-
lated from TCR-activated memory CD4+ T-cells express-
ing or lacking the Th17 marker CCR6 (Fig. 6c). Of note, 
the CCR6− fraction includes Th1 cells, while the CCR6+ 
fraction includes Th17 cells. The purity of nuclear frac-
tions was assessed by western blotting; this demonstrated 
the expression of the nuclear marker Histone H3 but 
the absence of the cytoplasmic marker β-actin (data not 
shown). For equal quantities of total nuclear proteins, the 
NF-κB DNA-binding activity was significantly higher in 
CCR6+ than CCR6− T-cells in 3/3 subjects (Fig. 6c). These 
results are consistent with previous findings by our group 
that CCR6+ compared to CCR6− T-cells are major HIV 
replication targets [104]. Thus, TCR triggering results in 
superior NF-κB nuclear translocation and DNA-binding 
activity in Th17 when compared to Th1. This difference 
highly likely contributes to enhanced transcription of the 
HIV genome in Th17 versus Th1.
Th17 versus Th1 proliferate in response to low intensity 
TCR triggering
The engagement of TCR induces complex modifications 
of cellular processes, including the production of effector 
cytokines and ultimately cell proliferation. In an effort to 
determine whether superior levels of Lck/ZAP-70 phos-
phorylation (Fig. 5) and NF-κB activation (Fig. 6) impact 
on the proliferation potential of Th17 versus Th1 cells, a 
CFSE dilution assay was used to measure at the single-
cell level the proliferation of memory CD4+ T-cells with 
intracellular expression of IL-17A only (Th17), IFN-γ 
only (Th1), or both IL-17 and IFN-γ (Th1Th17). Optimal 
IL-17A expression was observed when cells were stimu-
lated with CD3/CD28 Abs for three days and with PMA 
and Ionomycin in the presence of Brefledin A for addi-
tional 16 h (Fig. 7a). Th17 and Th1Th17 versus Th1 pro-
liferated at superior levels in 4/4 donors, and this was for 
three different concentrations of CD3 and CD28 Abs (0.1, 
0.25, and 0.5  µg/ml); differences were more remarkable 
for the lowest CD3/CD28 Abs concentration (Fig. 7a–c). 
Therefore, our results provide evidence that Th17 versus 
Th1 exhibit a superior ability to proliferate and produce 
IL-17A in response to relatively low TCR triggering sig-
nals. Our results are consistent with previous studies by 
other groups reporting on the induction of Th17 effector 
functions upon low strength TCR activation [105, 106].
MAP3K4, PTPN13, and SERPINB6 act as HIV permissiveness 
factors
Other differentially expressed transcripts included 
MAP3K4 and PTPN13 that were up regulated (Addi-
tional file  5: Figure S2) and SERPINB6 that was down 
regulated in Th17 versus Th1 (Tables 1, 2). Of note, SER-
PINB6, an intracellular serine protease inhibitor, was 
previously identified as an HDF in genome-wide siRNA 
screens performed in HeLa cells [58]. We assessed the 
effect of RNA interference against MAP3K4, PTPN13, 
and SERPINB6 on the efficacy of HIV-DNA integration 
in memory CD4+ T-cells. The results in Fig.  8 demon-
strate that decreased expression of MAP3K4, PTPN13, 
and SERPINB6 mRNA was associated with a statisti-
cally significant reduction in levels of integrated HIV-
DNA; this indicates that these molecules restrict viral 
replication prior to integration. Thus, in addition to the 
identification of MAP3K4 and PTPN13 as novel positive 
regulators of HIV replication preferentially expressed in 
Th17 cells, we confirm SERPINB6 is indeed a HDF. The 
detailed molecular mechanisms by which MAP3K4 and 
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PTPN13 regulate HIV integration in Th17 cells remain to 
be investigated.
Discussion
HIV-1 targets for infection and subsequent depletion 
cells of the immune system that play key roles in the 
defense against pathogens, including the Th17-polarized 
CD4+ T-cells [19, 37, 38, 50]. The unique developmen-
tal plasticity (e.g., ability to convert into Th1, Th2 and 
Tregs [107, 108]), pathogen-specificity and functional 
heterogeneity [13, 14, 15, 109, 110, 111, 112], together 
with their long-lived properties [52–54], position Th17 
cells at the very core of the immune system. Given their 
predominant location at mucosal surfaces, including the 
Fig. 6 NF‑κB nuclear translocation and DNA‑binding activity in CCR4+CCR6+ Th17 versus CXCR3+CCR6− Th1 cells. a, b Matched Th17 and Th1 
subsets were isolated and stimulated via CD3/CD28 for 3 days as described in Fig. 1. Cells were seeded on poly‑l‑lysine coated slides, and intracel‑
lular staining was performed with rabbit anti‑human NF‑kB followed by goat anti‑rabbit AlexaFluor 488 Abs. Slides were mounted with the ProLong 
Gold Antifade reagent containing the nuclear dye DAPI. Slides were then observed by confocal microscopy. a NF‑κB expression was observed under 
a 100× oil‑immersion objective (NA = 1.46) in a spinning‑disc confocal mode system. Shown are maximum intensity z projection of z stack of Th17 
and Th1 cells from one donor representative of observations made with two different donors. b The relative expression of intra‑nuclear NF‑κB was 
quantified in cells from two different donors using the Image J software based on observations by epifluorescence with a 40x Oil immersion objec‑
tive (NA = 1.40). Horizontal red lines indicate median values. Unpaired t test p values are indicated in the figure. c Memory CCR6+ and CCR6− CD4+ 
T‑cell subsets were enriched by MACS and sorted by FACS as previously reported [104]. Cells were stimulated via CD3/CD28, as in Fig. 1, and nuclear 
fractions were extracted. Shown is the ELISA quantification of NF‑κB‑p65 DNA‑binding activity in nuclear extracts from matched CCR6+ and CCR6− 
subsets isolated from three different HIV‑uninfected donors (mean ± SD of triplicate wells). Student t test p values are indicated in the figures
(See figure on next page.) 
Fig. 7 Proliferation of CD4+ T‑cells expressing IL‑17A versus IFN‑γ in response to low TCR triggering. Memory CD4+ T‑cells were isolated from PBMCs 
of four different HIV‑uninfected donors by negative selection using magnetic beads. Cells were loaded with CFSE (0.5 µM) and cultured in the pres‑
ence of different doses of immobilized CD3 and soluble CD28 Abs (0.1, 0.25, or 0.5 µg/ml) for 3 days. Cells were then stimulated with PMA/Ionomycin 
in the presence of Brefeldin A for 18 h. Intracellular staining was performed with IL‑17A and IFN‑γ Abs. Based on the expression of IL‑17A and/or IFN‑
γ, three cell subsets were identified as follows: Th1 (IL‑17A−IFN‑γ+), Th17 (IL‑17A+IFN‑γ−), and Th1Th17 (IL‑17A+IFN‑γ+). The frequency of proliferating 
cells (CFSElow) was analyzed in each of the three cytokine‑expressing subsets. a Shown are flow cytometry results in one representative donor out of 
four. Shown are statistical analyses of absolute (b) and relative (Th1Th17 proliferation levels were considered 100 %) c proliferation (CFSElow) levels in 
Th1, Th17, and Th1Th17 cells from four different donors. Paired t test p values are indicated on the graphs
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gut-associated lymphoid tissues (GALT), Th17 cells rep-
resent the first HIV/SIV targets at the portal sites of entry 
[25, 113]. Quantitative and qualitative alterations in Th17 
cells within the GALT represent a major cause of HIV/
SIV disease progression [24, 25, 114, 115, 116, 117, 118, 
119]. Therefore, understanding molecular mechanisms 
Fig. 8 Effects of MAP3K4, PTPN13, and SERPINB6 RNA interference on HIV‑1 integration in memory CD4+ T cells. RNA interference experiments 
were performed on memory CD4+ T‑cells as described in the Fig. 7 legend. a Shown is the experimental flow chart. Briefly, cells were stimulated via 
CD3/CD28 for 2 days, washed and nucleofected with siRNA pools (1 µM) specific for MAP3K4, PTPN13, and SERPINB6 or a non‑targeting siRNA (NT). 
Nucleofected cells were cultured in the presence of IL‑2 (5 ng/ml) for 24 h and then exposed to the HIV NL4.3BAL‑GFP strain (50 ng HIV‑p24/ml) 
for 3 h at 37 °C. Infected cells were cultured in the presence of IL‑2 (5 ng/ml) for 3 days. b The yield of siRNA silencing was determined by real‑time 
RT‑PCR quantification of MAP3K4, PTPN13, and SERPINB6 mRNA expression in cells nucleofected with targeting (MAP3K4, PTPN13, SERPINB6) versus 
non‑targeting (NT) siRNA. Shown are results obtained with cells from two to five different donors. c Levels of integrated HIV‑DNA were quantified 
by nested real‑time PCR in cells harvested at day three post‑infection. HIV‑DNA copy numbers were normalized relative to CD3 expression. Shown 
is relative HIV‑DNA integration in targeting versus NT siRNA conditions (normalized to the maximal value considered to be 100 % in NT condition); 
the values above graphs are integrated HIV‑DNA copies per 106 cells in NT nucleofected cells (mean ± SD of triplicate wells). Paired t test values are 
indicated on the graphs
Page 15 of 23Cleret‑Buhot et al. Retrovirology  (2015) 12:102 
of HIV permissiveness in Th17 cells represents a major 
research priority. Studies by our group [37], confirmed 
by others [38, 50], demonstrated that CCR4+CCR6+Th17 
and CXCR3+CCR6+Th1Th17 cells are highly permissive, 
while CXCR3+CCR6−Th1 are relatively resistant to R5 
and X4 HIV infection, and CCR4+CCR6−Th2 are per-
missive to X4 HIV only [37]. In this manuscript, we used 
a systems biology approach to unveil molecular mecha-
nisms of HIV replication in Th17 cells by comparing 
their transcriptome to those of Th1, Th2 and Th1Th17 
cells. We reveal here for the first time to our knowledge a 
molecular signature associated with HIV permissiveness 
in primary Th17 cells.
Our genome-wide transcriptional profiles demon-
strated superior expression of KLF2 in Th17 compared 
to Th1 cells. These findings were confirmed by RT-PCR. 
KLF2 is a transcription factor that binds to the CCR5 
promoter and positively regulates its expression and the 
subsequent permissiveness of CD4+ T-cells to R5 HIV 
[76]. CCR5 is indeed a key co-receptor for HIV entry 
[120] and one of the major determinants of disease pro-
gression [121, 122] involved in the early phases of HIV 
acquisition at mucosal surfaces [123, 124]. Activated 
CCR5+ T-cells are enriched within the GALT and repre-
sent the first HIV targets [125]. However, superior HIV 
permissiveness in Th17 versus Th1 is not the reflection of 
their superior CCR5 expression ex vivo [37]; this suggests 
that CCR5 is essential but not sufficient to support R5 
HIV entry and/or subsequent replication. Nevertheless, 
the stability of CCR5 expression upon TCR triggering in 
long-term cultures was not investigated in our system, 
and therefore the potential role of KLF2 in regulating 
superior/stable CCR5 expression in Th17 cells cannot be 
excluded. The autocrine production of CCR5 ligands was 
previously identified as a mechanism by which CMV-
specific CD4+ T-cells are protected from HIV infection 
[126]. The overexpression of transcripts for CCR5 ligands 
observed in this study in Th1 versus Th17 is consistent 
with previous reports by our group [37] and others [50, 
114] where CCR5 ligand protein levels were investigated. 
Thus, the autocrine production of CCR5 ligands by Th1 
cells may contribute to limited HIV entry in Th1 cells. 
Despite any potential regulatory mechanisms at entry 
level, we report superior HIV-DNA integration in Th17 
versus Th1 cells upon exposure to both wild-type and 
VSV-G-pseudotyped HIV; this indicates that post-entry 
mechanisms contribute to viral permissiveness in Th17 
cells.
Upon receptor-mediated entry, HIV-1 uses the host-
cell molecular machinery to ensure its reverse transcrip-
tion, integration and transcription [59, 60]. Large siRNA 
screens performed on cell lines identified networks of 
HDFs acting at different levels of the viral life cycle [56, 
57, 58, 84]. Very few HDF identification studies were 
performed on primary cells [127–129]. JAK1 is one of 
the very few HDFs identified in more than two siRNA 
screens that is also included in the NCBI HIV interaction 
database [60]. Of particular importance, our microarrays 
revealed an up-regulation of JAK1 transcripts in Th17 
versus Th1. JAK1 is a tyrosine kinase associated with the 
signaling through the receptors of type I and II cytokines; 
activation of JAK1 induces STAT3 phosphorylation in 
response to IL-21 stimulation [130]. Consistent with 
JAK1 up-regulation in Th17 cells, the JAK signaling path-
way is altered in subjects with Hyper IgE syndrome that 
exhibit mutations in STAT3 and subsequent Th17 defi-
ciency [131]. JAK1 antagonists were reported to interfere 
with Th17 polarization in a mouse model of psoriasis 
[132]. Considering the fact that JAK antagonists inhibit 
HIV replication and reactivation [133], JAK1 may repre-
sent a novel therapeutic target to interfere with infection 
in Th17 cells.
Despite a low degree of overlap among individual 
HDFs identified in different siRNA screens [56, 57, 58, 
84], pathways such as NF-κB, peroxisome proliferator-
activated receptor (PPAR), and retinoic acid receptor 
were identified as being important for HIV permissive-
ness in at least two distinct studies [59, 60]. A previous 
study by our group demonstrated that the transcription 
factor PPARγ is expressed at superior levels in Th1Th17 
versus Th1 and acts as a negative regulator of HIV repli-
cation [129]. Of note, PPARγ is also an intrinsic negative 
regulator of Th17 polarization [134]. Therefore, mecha-
nisms involved in Th17 polarization and HIV replica-
tion are overlapping. The present transcriptional profiles 
consistently demonstrated superior expression of PPARγ 
in Th17 versus Th1 cells. These findings provide further 
evidence that Th17, similar to Th1Th17 cells [129], are 
endowed with intrinsic mechanisms that control HIV 
permissiveness, mechanisms that should be targeted 
therapeutically.
Consistent with differential HIV replication in Th17, 
Th1Th17, Th1, and Th2 memory CD4+ T-cell subsets 
[37], the present genome-wide transcriptional profil-
ing revealed the remarkable transcriptional differences 
between Th17 and Th1 cells. Gene set variation analysis 
revealed unique pathways enriched in Th17 versus Th1 
cells, including TCR signaling, T-helper differentiation, 
IL-7 signaling, nuclear receptor transcription, and circa-
dian repression of expression by REV-ERBα. Therefore, 
it is reasonable to assume that pathways preferentially 
expressed in Th17 cells are exploited by HIV for success-
ful replication.
Similar to Th2 and in contrast to Th1 [135], Th17 polar-
ization depends on low strength TCR signals [105]. Con-
sistently, we found an enriched expression of transcripts 
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linked to the TCR signaling cascade in Th17 versus Th1, 
including the major kinases Lck and ZAP-70. These dif-
ferences were validated by RT-PCR at the population 
level and further visualized/quantified at the single-
cell level by confocal microscopy. Of note, Lck facili-
tates assembly of HIV-1 by targeting HIV-1 Gag to the 
plasma membrane in T cells [136], while ZAP-70 kinase 
regulates HIV cell-to-cell spread and virological syn-
apse formation [71]. Superior expression of phosphoryl-
ated active forms of Lck and ZAP-70 in Th17 versus Th1 
cells coincided with superior expression of transcripts 
for multiple kinases and phosphatases downstream from 
the TCR. Among transcripts associated with the TCR 
reactome, our RNA interference experiments identified 
MAP3K4 and PTPN13 as positive regulators of HIV rep-
lication in Th17 cells. The phosphorylation of p38 MAPK 
by MAP3K4 was previously linked to Th17 polarization 
signals [137]. We previously reported MAP3K4 up-reg-
ulation in HIV-permissive Th1Th17 cells [129]. PTPN13, 
a tyrosine phosphatase involved in the negative regula-
tion of Fas-dependent apoptosis upon TCR triggering 
[138–140], was identified as a Th1Th17 marker [62, 129]. 
Here, we confirmed by RT-PCR the exclusive expression 
of PTPN13 mRNA in Th17 versus Th1. Mechanisms by 
which MAP3K4 and PTPN13 regulate HIV replication 
remain to be further examined, but they are likely linked 
to the control of the state of cellular activation upon TCR 
engagement.
The replication of HIV is limited in resting CD4+ 
T-cells [91] through restriction mechanisms that are 
abrogated by activation/proliferation induced upon 
engagement of the TCR and/or cytokine receptors 
[141–144]. Our functional studies demonstrated that 
CD3/CD28 engagement resulted in superior cell pro-
liferation and NF-κB nuclear translocation as well as 
DNA binding activity in Th17 versus Th1. Indeed, in 
contrast to IFN-γ+, IL-17A+ cells proliferated effi-
ciently in response to low concentrations of CD3/CD28 
Abs. A study by Santarlasci et al. reported an impaired 
ability of Th17 cells to proliferate [145]. This report is 
in contrast to our results on superior NF-κB activa-
tion and proliferation in Th17 versus Th1 cells. These 
discrepancies may be explained by results generated 
with polyclonal subsets producing IL-17 ex  vivo in 
our studies versus Th17 clones in studies by Santar-
lasci et al. 145], clones that are potentially exhausted or 
senescent due to long-term maintenance in vitro. Our 
findings are in line with publications by other groups 
on the long lived properties of Th17 cells [52–54]. In 
addition to the ability of NF-κB to regulate transcrip-
tion of multiple host genes that may be critical for HIV 
permissiveness, NF-κB directly binds to the HIV pro-
moter and positively regulates its activity [102, 103]. 
Accordingly, genome-wide siRNA screens for HDFs 
identified the NF-κB pathway as being a key regulator 
of HIV permissiveness [59, 60]. In our transcriptional 
studies, MALT1 (a paracaspase involved in NF-κB 
activation [68]) and TRIM8 (a regulator of NF-κB and 
STAT3-dependent signaling cascades [81, 82] and doc-
umented HDF [57]) were also found up regulated in 
Th17 versus Th1 cells. Of particular interest, MALT1 
was recently linked to Th17 polarization [69]. These 
results emphasize complex host cell-pathogen interac-
tions by which HIV takes advantage of universal and 
Th17-specific proximal/distal components of the TCR 
signaling cascade for its efficient replication.
Our findings that Th17 cells proliferate in response 
to weak TCR signals are consistent with recent studies 
demonstrating that miR-181a, a microRNA involved in 
the regulation of TCR activation [146], is preferentially 
induced under Th17 polarizing conditions [106]. MiR-
181a lowers the TCR activation threshold through the 
modulation of ERK phosphorylation [106]. Of note, miR-
181a is also involved in the post-transcriptional regulation 
of SAMHD1 [147], an HIV restriction factor expressed in 
quiescent CD4+ T-cells [148] that limits HIV reverse tran-
scription by its dNTPase [149] and RNase activity [150]. 
The restriction ability of SAMHD1 is negatively regu-
lated by phosphorylation [151]. Our microarrays were not 
designed to detect microRNAs and did not reveal differ-
ences in SAMHD1 mRNA expression. Further studies are 
needed to clarify the potential role of SAMHD1 in con-
trolling HIV replication in Th17 cells.
Conclusions
This study reveals a unique molecular signature of HIV 
permissiveness in Th17 cells (e.g., PPARG, PAK2, KLF2, 
PTEN, ITGB7, ATG16L1, Alix/AIP1/PDCD6IP, LGALS3, 
JAK1, TRIM8, MALT1, FOXO3, ARNTL, ABCB1, 
TNFSF13B/BAFF, and CDKN1B) and provides evidence 
that a unique TCR signaling cascade is favorable to HIV 
replication in Th17 cells. The current identification of 
novel Th17-specific HDFs is instrumental for design-
ing novel therapeutic strategies aimed at interfering 




Healthy HIV-uninfected donors were recruited at the 
Montreal Chest Institute, McGill University Health Cen-
tre, and Centre Hospitalier de l’Universite de Montreal 
(CHUM, Montreal, Quebec, Canada). Large quantities of 
PBMCs (109–1010 cells) were collected by leukapheresis 
as previously described [152].
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Ethics statement
This study, using PBMC samples from healthy HIV-unin-
fected subjects, was conducted in compliance with the prin-
ciples included in the Declaration of Helsinki. This study 
received approval from the Institutional Review Board 
of the McGill University Health Centre and the CHUM-
Research Centre, Montreal, Quebec, Canada. All human 
subjects that donated biological samples for this study pro-
vided written informed consent for their participation in the 
study. All human subjects agreed with the publication of the 
subsequent results generated using the samples.
Flow cytometry analysis
Fluorochrome-conjugated Abs used for polychromatic 
flow cytometry analysis were CD3-Pacific Blue (UCHT1), 
CD4-Alexa700 (RPA-T4), CD45RA-APC-Cy7 (custom), 
CCR4-PE-Cy7 (1G1), CXCR3-PE-Cy5 (1C6), CCR6-
PE (11A9), Ki67-FITC, IFN-γ-AlexaFluor 700 (B27) 
(BD Pharmingen), CD56-FITC (MEM188), IL-17-PE 
(64DEC17) (eBioscience), HIV-p24-FITC (FH190-1-1) 
(Beckman Coulter), CD8-FITC (BW135/80), and CD19-
FITC (LT19) (Miltenyi). A viability dye (Molecular 
Probes® LIVE/DEAD® Fixable Dead Cell Stain Kits, Inv-
itrogen) was used to exclude dead cells. Cells were stained 
and analyzed by FACS using the BD LSRII cytometer and 
the FlowJo software, as previously described [129].
Magnetic (MACS) and fluorescence activated cell sorting 
(FACS)
Total or memory CD4+ T-cells were enriched from 
PBMC by negative selection using magnetic beads 
(MACS, Miltenyi), with a purity >95  % as previously 
described [37, 104]. Then, cells were stained with 
CD45RA-APC-Cy7, CCR6-PE, CCR4-PE-Cy7, CXCR3-
PE-Cy5 Abs and a cocktail of FITC-conjugated Abs 
to exclude CD8+ T-cells (CD8), NK cells (CD56), and 
B cells (CD19). The sorting gates were set on FITCneg 
memory (CD45RAneg) T-cells. Four subsets were sorted 
by flow cytometry (BDAria II): CXCR3+CCR4−CCR6− 
(CXCR3+Th1), CXCR3−CCR4+CCR6− (CCR4+Th2), 
CXCR3−CCR4+CCR6+ (CCR4+CCR6+Th17), and 
CXCR3+CCR4−CCR6+ (CXCR3+CCR6+Th1Th17). In 
other experiments, memory CCR6+ and CCR6− T-cells 
were sorted upon staining with CD45RA-APC-Cy7 and 
CCR6-PE Abs as well as a mixture of FITC-conjugated 
CD8, CD56, and CD19 Abs. A viability dye was used to 
exclude dead cells. Post-sort FACS analysis demonstrated 
sorted T-cell subsets were >99 % pure, as reported earlier 
[37, 104, 129].
Genome‑wide transcriptional profiling
Matched memory CD4+ T-cell subsets were isolated by 
FACS from five different HIV-uninfected donors and 
stimulated with immobilized CD3 and soluble CD28 
(1 µg/ml) for 3 days. Total RNA was isolated using RNe-
asy columns kit (Qiagen) according to the manufac-
turer’s protocol. RNA quantity was determined by Pearl 
nanophotometer (Implen, Germany) (106 cells yielded 
1–5 µg RNA). Genome-wide analysis of gene expression 
was performed on total RNA by Génome Québec (Mon-
treal, Quebec, Canada). Briefly, the quality of total RNA 
was tested using the Agilent 2100 Bioanalyzer chip. High 
quality RNA was reverse transcribed and hybridized on 
the Illumina HumanHT-12 v4 Expression BeadChip pro-
viding coverage for more than 47,000 transcripts and 
known splice variants across the human transcriptome.
Transcriptional profiling analysis
Gene expression analyses were performed as previously 
described [129]. Briefly, after quality control of the microar-
ray data, the resulting expression matrix was used as input 
for linear modelling using Bioconductor’s limma package, 
which estimates the fold-change among predefined groups 
by fitting a linear model and using an empirical Bayes 
method to moderate standard errors of the estimated log-
fold changes for expression values from each gene. A linear 
mixed model was designed with the population as a fixed 
effect and the donor ID as a random effect. P values from 
the resulting comparison were adjusted for multiple test-
ing according to the method of Benjamini and Hochberg 
(1995). This method controls the false discovery rate (FDR), 
which was set to 0.05 in this analysis. Determination of reg-
ulated gene expression is based on p values or adjusted p 
values as indicated in the figure or table legends. The entire 
microarray dataset and technical information requested by 
Minimum Information About a Microarray Experiment 
(MIAME) are available at the Gene Expression Omnibus 
(GEO) database under accession number GSE70396. Dif-
ferentially expressed genes (cut-off 1.3-fold; p < 0.05) were 
classified through Gene Ontology using the NetAffx web-
based application (Affymetrix). Corresponding heat maps 
for biological function categories were generated using pro-
gramming language R. Enrichment Statistics (ES) from the 
gene set variation analysis were calculated as the maximum 
distance of the random walk statistic using the GSVA bio-
conductor package [153] on the same databases described 
in Bernier et al. [129]. Differential expression analysis of the 
ES was performed with the limma bioconductor package 
following the same model applied to probe-level expres-
sion. The gene networks were generated through the use 
of ingenuity pathways analysis (Ingenuity® systems, http://
www.ingenuity.com).
Real‑time RT‑PCR
One step SYBR Green real-time RT-PCR (Qiagen) was 
carried out in a LightCycler 480 II (Roche) according 
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to manufacturer’s recommendations, as we previously 
reported [37, 104, 129]. Briefly, for standard curve prepa-
ration, 5-50  ng of total RNA were reverse transcribed 
using a SYBR Green mix (Qiagen) containing 0.5  μM 
primers. Agarose gel electrophoresis was used to visual-
ize the size of the amplification products. cDNA purifica-
tion was performed using the QIAquick Gel Extraction 
Kit (Qiagen). Serial dilutions of cDNA (20,000; 2000; 200; 
20; 2; 0.2 fgs) were used for the absolute quantification 
of target gene expression. QuantiTect Primer Assays for 
KLF2, PPARγ, ARNTL, ZAP-70, Lck, PTPN13, RORC, 
MAP3K4, and SERPINB6 were purchased from Qiagen. 
The expression of each gene was normalized relative to 
the internal control 28S rRNA levels (forward 5′-CGAG 
ATTCCTGTCCCCACTA-3′; reverse 5′-GGGGCCACC 
TCCTTATTCTA-3′, IDT). Melting curve analysis 
performed after real-time amplification revealed the 
uniformity of thermal dissociation profile for each ampli-
fication product. Samples without template or without 
reverse transcriptase were used as negative controls. 
Each RT-PCR reaction was performed in triplicate.
HIV infection and quantification of viral replication
The following HIV-1 molecular clones were used in this 
study: (1) replication-competent CCR5-using (R5) HIV 
NL4.3BAL; (2) replication-competent R5 NL4.3BAL-
GFP expressing gfp in place of nef; and (3) single-round 
VSVG-HIV-GFP, an env-deficient NL4.3 provirus pseu-
dotyped with the VSV-G envelope and expressing gfp in 
place of nef [37, 104, 129]. HIV stocks were produced, 
titrated, and used to infect cells (50 ng HIV-p24 per 106 
cells) as previously described [37, 104, 129]. HIV-p24 
levels were quantified in cell culture supernatants using 
a homemade ELISA [37, 104]. HIV-DNA integration was 
quantified in cell lysates by real-time nested PCR (105 
cells per test in triplicate; detection limit: three HIV-
DNA copies), as previously described [37, 104, 129, 154].
Fluorescence microscopy and quantitative image analysis
The visualization and quantification of protein expres-
sion was performed by confocal microscopy, as previously 
described [129]. Briefly, FACS-sorted Th17 and Th1 subsets 
were stimulated via CD3/CD28 for 3  days (1  μg/ml) and 
placed into poly-l-lysine-coated eight-wells glass culture 
slides (BD Biosciences) (105 cells/well). Cells were stained 
with primary Abs against total Lck (clone 73A5), total ZAP-
70 (clone 99F2), phosphorylated Lck on Tyr-394 (Santa Cruz 
Biotechnology) and Tyr-505 (clone 2751), phosphorylated 
ZAP-70 on Tyr319 (clone 65EA cross reacting with phos-
phorylated Syk on Tyr352), and NF-κB p65 (clone 3034) and 
Alexa Fluor 488-conjugated goat anti-rabbit Abs (Invitro-
gen) as secondary Abs. The above Abs were purchased from 
Cell Signaling Technology, unless otherwise specified. Slides 
were mounted using ProLong Gold Antifade medium with 
the nuclear dye DAPI (Invitrogen, Molecular Probes). Epi-
fluorescent and Spinning Disc confocal microscopy images 
were acquired out on an automated Cell Observer Z1® 
microscope (Carl Zeiss) using the AxioVision 4.8.2 software 
(Carl Zeiss). For the analysis of protein cellular localization, 
spinning disc confocal images were acquired using the 100× 
oil immersion objective (numerical aperture, NA: 1.46) and 
maximum intensity projection of 0.2 μm z-stack sections 
were realized using ImageJ software (NIH) after background 
subtraction. For statistical analysis of protein expression, 
random epi-fluorescent images were acquired with the 40× 
oil immersion objective (NA: 1.3). All acquisitions between 
the different T-cell subsets were performed with the same 
illumination status in the same run. Integrated density was 
measured after background subtraction with ImageJ soft-
ware. Data were compared by analysis of integrated density/
area for 50–100 cells/subset.
NF‑κB DNA‑binding activity
Nuclear extracts were obtained from activated CD4+ T-cells 
using the BD transfactor extraction kit (Clonetech Labo-
ratories). The active form of NF-κB p65 was quantified by 
ELISA (1 μg nuclear protein/test; Assay Designs & Stress-
gen). The specificity of NF-κB p65 DNA-binding was deter-
mined using wild-type and mutated NF-κB p65 duplex 
competitors, according to the manufacturer’s protocol.
CFSE dilution assay and intracellular cytokine staining
Cell proliferation was measured using the Carboxy Fluo-
rescein Succinimidyl Ester (CFSE) dilution assay, as pre-
viously described [155]. Briefly, memory CD4+ T-cells 
were loaded with CFSE and cultured in the presence of 
different doses of immobilized CD3 and soluble CD28 
Abs (0.5, 0.25, and 0.1 µg/ml) for 1, 2, 3, or 4 days. Cells 
were further stimulated with PMA (50 ng/ml, Sigma) and 
Ionomycin (1 µg/ml, Sigma) in the presence of Brefeldin 
A (2  μg/ml, Sigma) for 18  h. The production of IL-17A 
and IFN-γ was measured by intracellular staining with 
appropriate Abs using the BD cytofix/cytoperm fixation/
permeabilization solution kit (BD Biosciences) according 
to the manufacturer’s protocols.
RNA interference
RNA interference studies were performed as described 
earlier [129]. Briefly, PBMCs were thawed and rested 
overnight at 37  °C. Memory CD4+ T-cells were isolated 
from PBMC by negative selection using magnetic beads 
(Miltenyi Biotec). Cells were stimulated by CD3/CD28 
Abs for 2  days and nuclofected with 100  µM specific 
(MAP3K4, PTPN13, SERPINB6) or non-targeting (NT1) 
siRNA (ON-TARGETplus SMART pool, Dharmacon) 
using the Amaxa Human T cell Nucleofector Kit (Amaxa, 
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Lonza), according to the manufacturer’s protocol. Cells 
were suspended in the NF solution (100 µl/2 × 106 cells) 
and nucleofected using the Amaxa Nucleofector II Device 
and the human activated T-cell protocol (T-20). Cells 
(2 × 106) were transferred into 48-well plates containing 
1 ml of RPMI1640 (10 % FBS, 5 ng/ml IL-2, w/o antibi-
otics) and cultured for 24 h at 37 °C. Cells were exposed 
to HIV and cultured up to 9 days. Culture supernatants 
were harvested and media was refreshed every 3  days. 
The effectiveness of RNA silencing was assessed by SYBR 
Green real-time RT-PCR 24 h post-nucleofection. IL-17A 
production in cell supernatants was measured by ELISA 
at day 3 post-infection. Five days post-nucleofection, cells 
were stained with LIVE/DEAD® Fixable Dead Cell Stain 
Kit (invitrogen) and intracellular staining was performed 
using Ki67 Abs. Cell viability (vivid-) and cell cycle pro-
gression (Ki67+) were analyzed by FACS (BD LSRII).
Statistics
All statistical analyses were performed using the Prism 5 
(GraphPad software). Specifications are included in the 
figure legends.
Accession numbers
The entire microarray dataset and technical information 
requested by Minimum Information About a Microarray 
Experiment (MIAME) are available at the Gene Expres-
sion Omnibus (GEO) database under accession number 
GSE70396.
Additional files
Additional file 1: Table S1. The complete list of genes up regulated in 
Th17 versus Th1 subsets are included and classified based on p‑val‑
ues < 0.05 and FC cut‑off 1.3.
Additional file 2: Table S2. The complete list of genes down regu‑
lated in Th17 versus Th1 subsets are included and classified based on 
p‑values < 0.05 and FC cut‑off 1.3.
Additional file 3: Figure S1. a A heat map including the hierarchi‑
cal clustering of all differentially expressed genes in Th17 versus Th1 
subsets and b a heat map including top differentially expressed canonical 
pathways in Th17 versus Th1 subsets identified using Gene set variation 
analysis (GSVA; adj. p‑values < 0.05).
Additional file 4: Table S3. The complete list of canonical pathways 
differentially expressed in Th17 versus Th1 subsets were identified using 
GSVA and classified based on adj. p‑values < 0.05 and log FC.
Additional file 5: Figure S2. Included are top canonical pathways (C2) 
(a), transcription factors (C3) (b), and biological processes (C5) (c) that are 
differentially expressed between Th17 and Th1 subsets and were identi‑
fied using Gene set enrichment analysis (GSEA).
Additional file 6: Figure S3. A meta‑analysis for transcripts included in 
the NCBI HIV Interaction data base that were identified as top differentially 
expressed between Th17 and Th1 subsets.
Additional file 7: Figure S4. The T cell receptor signalling pathways was 
generated using the Ingenuity pathway analysis (IPA), with transcripts up 
and down regulated in Th17 versus Th1 subsets being highlighted in red 
and green, respectively.
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